Correction: Association of adrenal function and disease severity in community-acquired pneumonia (PLoS ONE (2014) 9, 6 (e99518) DOI: 10.1371/journal.pone.0099518);Association of adrenal function and disease severity in community-acquired pneumonia

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mueller, Cornelia ^a   Blum, Claudine A ^a   Trummler, Michael ^b   Stolz, Daiana ^c   Bingisser, Roland ^c   Mueller, Christian ^c   Tamm, Michael ^c   Mueller, Beat ^d   Schuetz, Philipp ^d   Christ Crain, Mirjam ^a  

^a UniversityHospital ^*  (Switzerland)

^b Bio Analytica AG   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Medical University Clinic   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; PRASTERONE; PRASTERONE SULFATE;

ADRENAL FUNCTION; ADULT; AGE; AGED; ANDROGEN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HORMONE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; ADRENAL GLAND; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; METABOLISM; MIDDLE AGED; PNEUMONIA; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADRENAL GLANDS; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA; PROGNOSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84902573205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102637     Document Type: Erratum

References (19)

1. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, et al. (2009) Newperspectives on community-acquired pneumonia in 388 406 patients. Resultsfrom a nationwide mandatory performance measurement programme in healthcarequality. Thorax 64: 1062-1069.
2. Girard TD, Ely EW (2007) Bacteremiaand sepsis in older adults. Clin Geriatr Med 23: 633-647, viii.
3. Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schafer T (2007) Approachesto estimate the population-based incidence of community acquired pneumonia. J Infect 55: 233-239. (Pubitemid 47248481)
4. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, et al. (1997) Aprediction rule to identify low-risk patients with community-acquired- pneumonia. N Engl J Med 336: 243-250. (Pubitemid 27044625)
5. Beishuizen A, Thijs LG, Vermes I (2002) Decreased levels of dehydroepian-drosterone sulphate in severe critical illness:a sign of exhausted adrenal reserve? Crit Care 6: 434-438.
6. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, et al. (2006) Procalcitoninguidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174: 84-93. (Pubitemid 43955248)
7. Kolditz M, Halank M, Schulte-Hubbert B, Hoffken G (2010) Adrenalfunction is related to prognosis in moderate community-acquired pneumonia. EurRespir J 36: 615-621.
8. Blum CA, Mueller C, Schuetz P, Fluri F, Trummler M, et al. (2013) Prognosticvalue of dehydroepiandrosterone-sulfate and other parameters of adrenalfunction in acute ischemic stroke. PLoS One 8: e63224.
9. Chrousos GP (1995) The hypothalamic-pituitary-adrenal axisand immune-mediated inflammation. N Engl J Med 332: 1351-1362.
10. Christ-Crain M, Stolz D, Jutla S, Couppis O, Muller C, et al. (2007) Freeand total cortisol levels as predictors of severity and outcome in communityacquiredpneumonia. Am J Respir Crit Care Med 176: 913-920. (Pubitemid 350097081)
11. Vermes I, Beishuizen A (2001) Thehypothalamic-pituitary-adrenal response to critical illness. BestPract Res Clin Endocrinol Metab 15: 495-511.
12. Oberbeck R, Kobbe P (2010) Dehydroepiandrosterone (DHEA):a steroid with multiple effects. Is there any possible option in the treatmentof critical illness? Curr Med Chem 17: 1039-1047.
13. Oberbeck R, Dahlweid M, Koch R, vanGriensven M, Emmendorfer A, et al. (2001) Dehydroepiandrosterone decreases mortalityrate and improves cellular immune function during polymicrobial sepsis. CritCare Med 29: 380-384. (Pubitemid 32171785)
14. Schmitz D, Kobbe P, Wegner A, Hammes F, Oberbeck R (2010) Dehydroe-piandrosteroneduring sepsis: does the timing of administration influence the effectiveness. J SurgRes 163: e73-77.
15. Arlt W, Hammer F, Sanning P, Butcher SK, Lord JM, et al. (2006) Dissociation of serum dehydroepiandrosterone and dehydroepiandrosteronesulfate in septic shock. J Clin Endocrinol Metab 91: 2548-2554. (Pubitemid 44024616)
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2007) The Strengthening the Reporting ofObservational Studies in Epidemiology (STROBE) statement:guidelines for reporting observational studies. Lancet 370: 1453-1457.
17. Radford DJ, Wang K, McNelis JC, Taylor AE, Hechenberger G, et al. (2010) Dehydroepiandrosterone sulfate directlyactivates protein kinase C-beta to increase human neutrophil superoxidegeneration. Mol Endocrinol 24: 813-821.
18. Rosenfeld RS, Hellman L, Roffwarg H, Weitzman ED, Fukushima DK, et al. (1971) Dehydroisoandrosterone is secreted episodicallyand synchronously with cortisol by normal man. J Clin EndocrinolMetab 33: 87-92.
19. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF (1999) DHEA and DHEA-S:a review. J Clin Pharmacol 39: 327-348.